Dr. John K. Cini Ph.D. is the Chief Scientific Officer & Co-Founder at Sonnet BioTherapeutics Inc.
As the Chief Scientific Officer & Co-Founder of Sonnet BioTherapeutics Inc, the total compensation of Dr D at Sonnet BioTherapeutics Inc is 302,923$. There are 3 executives at Sonnet BioTherapeutics Inc getting paid more, with Dr. Pankaj Mohan Ph.D. having the highest compensation of 792,166$.
Dr D is 68, he's been the Chief Scientific Officer & Co-Founder of Sonnet BioTherapeutics Inc since . There are no older and 6 younger executives at Sonnet BioTherapeutics Inc.
John's mailing address filed with the SEC is 100 OVERLOOK CENTER, SUITE 102, , PRINCETON,, NJ, 08540.
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over 53,380$ worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth 290,512$ . The most active insiders traders include Pankaj Mohan、Donald J. Griffith、Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of 21,474$. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth 12,739$.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: